BC Week In Review | Nov 11, 2013
Company News

A.P. Pharma management update

A.P. Pharma Inc. (OTCBB:APPA), Redwood City, Calif.   Business: Drug delivery   Hired: Brian Drazba as VP of finance and CFO, formerly VP of finance and chief accounting officer of Ista Pharmaceuticals Inc. , which Bausch...
BC Week In Review | Jun 3, 2013
Company News

Bausch + Lomb ophthalmic news

Bausch + Lomb said that its ISTA Pharmaceuticals Inc. subsidiary will pay about $34 million in civil and criminal fines to the U.S. government to settle litigation involving conduct by ISTA that occurred between January...
BC Week In Review | Apr 15, 2013
Clinical News

Prolensa bromfenac regulatory update

Bausch + Lomb said FDA approved Prolensa bromfenac to treat pain and ocular inflammation following cataract surgery. The product is a once-daily 0.07% topical non-steroidal anti-inflammatory ophthalmic solution and will be available in 1.6 and...
BC Week In Review | Apr 8, 2013
Company News

Aerie Pharmaceuticals board of directors update

Aerie Pharmaceuticals Inc. , Bedminster, N.J.   Business: Ophthalmic   Appointed: Vicente Anido as chairman, formerly president and CEO of Ista Pharmaceuticals Inc. , which Bausch + Lomb Inc. acquired  ...
BC Week In Review | Apr 1, 2013
Company News

Revance management update

Revance Therapeutics Inc. , Newark, Calif.   Business: Dermatology   Hired: Lauren Silvernail as CFO and EVP of corporate development, formerly VP of corporate development and CFO of Ista Pharmaceuticals Inc. , which Bausch + Lomb Inc....
BC Week In Review | Feb 18, 2013
Company News

Kolltan management update

Kolltan Pharmaceuticals Inc. , New Haven, Conn.   Business: Cancer, Antibodies   Hired: Jane Henderson as SVP and CBO, formerly VP of business development at Ista Pharmaceuticals Inc. , which Bausch + Lomb Inc. acquired  ...
BC Week In Review | Jun 25, 2012
Clinical News

Prolensa bromfenac regulatory update

Bausch + Lomb submitted an NDA to FDA for Prolensa bromfenac to treat pain and ocular inflammation following cataract surgery. The product is a once-daily topical non-steroidal anti-inflammatory ophthalmic solution. Bausch + Lomb gained U.S....
BC Week In Review | Jun 11, 2012
Company News

Bausch + Lomb, Ista deal

Bausch + Lomb completed its acquisition of fellow ophthalmic company Ista for $9.10 per share in cash, or about $500 million (see BioCentury, April 2). Bausch + Lomb Inc. , Rochester, N.Y.   Ista Pharmaceuticals Inc....
BC Week In Review | May 21, 2012
Clinical News

Prolensa bromfenac: Additional Phase III data

Additional data from a double-blind, U.S. Phase III trial in 220 patients undergoing unilateral cataract surgery showed that 49.1% of patients receiving once-daily Prolensa achieved complete absence of ocular inflammation at day 14 post-surgery, the...
BC Week In Review | May 14, 2012
Clinical News

Beposone: Phase II data

Top-line data from a double-blind, U.S. Phase II trial in about 600 patients aged 12 and older with allergic rhinitis due to Mountain Cedar pollen showed that twice-daily Beposone nasal spray significantly reduced total nasal...
Items per page:
1 - 10 of 333
BC Week In Review | Nov 11, 2013
Company News

A.P. Pharma management update

A.P. Pharma Inc. (OTCBB:APPA), Redwood City, Calif.   Business: Drug delivery   Hired: Brian Drazba as VP of finance and CFO, formerly VP of finance and chief accounting officer of Ista Pharmaceuticals Inc. , which Bausch...
BC Week In Review | Jun 3, 2013
Company News

Bausch + Lomb ophthalmic news

Bausch + Lomb said that its ISTA Pharmaceuticals Inc. subsidiary will pay about $34 million in civil and criminal fines to the U.S. government to settle litigation involving conduct by ISTA that occurred between January...
BC Week In Review | Apr 15, 2013
Clinical News

Prolensa bromfenac regulatory update

Bausch + Lomb said FDA approved Prolensa bromfenac to treat pain and ocular inflammation following cataract surgery. The product is a once-daily 0.07% topical non-steroidal anti-inflammatory ophthalmic solution and will be available in 1.6 and...
BC Week In Review | Apr 8, 2013
Company News

Aerie Pharmaceuticals board of directors update

Aerie Pharmaceuticals Inc. , Bedminster, N.J.   Business: Ophthalmic   Appointed: Vicente Anido as chairman, formerly president and CEO of Ista Pharmaceuticals Inc. , which Bausch + Lomb Inc. acquired  ...
BC Week In Review | Apr 1, 2013
Company News

Revance management update

Revance Therapeutics Inc. , Newark, Calif.   Business: Dermatology   Hired: Lauren Silvernail as CFO and EVP of corporate development, formerly VP of corporate development and CFO of Ista Pharmaceuticals Inc. , which Bausch + Lomb Inc....
BC Week In Review | Feb 18, 2013
Company News

Kolltan management update

Kolltan Pharmaceuticals Inc. , New Haven, Conn.   Business: Cancer, Antibodies   Hired: Jane Henderson as SVP and CBO, formerly VP of business development at Ista Pharmaceuticals Inc. , which Bausch + Lomb Inc. acquired  ...
BC Week In Review | Jun 25, 2012
Clinical News

Prolensa bromfenac regulatory update

Bausch + Lomb submitted an NDA to FDA for Prolensa bromfenac to treat pain and ocular inflammation following cataract surgery. The product is a once-daily topical non-steroidal anti-inflammatory ophthalmic solution. Bausch + Lomb gained U.S....
BC Week In Review | Jun 11, 2012
Company News

Bausch + Lomb, Ista deal

Bausch + Lomb completed its acquisition of fellow ophthalmic company Ista for $9.10 per share in cash, or about $500 million (see BioCentury, April 2). Bausch + Lomb Inc. , Rochester, N.Y.   Ista Pharmaceuticals Inc....
BC Week In Review | May 21, 2012
Clinical News

Prolensa bromfenac: Additional Phase III data

Additional data from a double-blind, U.S. Phase III trial in 220 patients undergoing unilateral cataract surgery showed that 49.1% of patients receiving once-daily Prolensa achieved complete absence of ocular inflammation at day 14 post-surgery, the...
BC Week In Review | May 14, 2012
Clinical News

Beposone: Phase II data

Top-line data from a double-blind, U.S. Phase II trial in about 600 patients aged 12 and older with allergic rhinitis due to Mountain Cedar pollen showed that twice-daily Beposone nasal spray significantly reduced total nasal...
Items per page:
1 - 10 of 333